New drug targets rare lung cancer subtype in early trial
NCT ID NCT07551635
First seen May 02, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study tests an experimental drug called FHD-286 in people with a specific type of small-cell lung cancer that has a marker called POU2F3. Participants must have already tried at least one standard chemotherapy. The drug is taken daily in 3-week cycles, and researchers will measure how many people's tumors shrink or disappear. This is a small, early-phase trial with 20 participants to see if the drug works and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.